Short-acting beta2-agonist refills are greater in patients with moderate/severe persistent asthma vs those with intermittent/mild persistent asthma.

Researchers evaluated this relationship in asthma as a whole, as well as in mild, moderate and severe persistent asthma subgroups, using logistic regression analysis.

Patients with mild to moderate asthma and self-reported asthma control may have elevated levels of fractional exhaled nitric oxide and eosinophils, according to a poster presented at the European ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the ...

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the ...

Now, the comorbidities could be both type 2 and non-type 2 comorbidities -- and really focusing on treatable traits and understanding globally how asthma is impacting our patients, targeting all ...

About the study In the present study, researchers examined the relationship between mild-to-moderate SARS-CoV-2 infection and asthma control after recovery from infection.

There was an increased risk for long COVID among patients with poor asthma control including those with asthma attacks (OR, 1.47; 95% CI, 1.09-1.97) and emergency room (ER) visits for asthma (OR, 1.52 ...

Chipps BE, et al. Efficacy and safety of albuterol/budesonide (PT027) in mild-to-moderate asthma: Results of the DENALI study. American Thoracic Society International Conference 2022.

AZ showed that use of inhaler Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol.